Cargando…

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

PURPOSE: To characterize the population pharmacokinetics (PKs) of subcutaneous (SC) and intravenous (IV) trastuzumab in early breast cancer (EBC), assess the impact of covariates on trastuzumab PK, and evaluate fixed (nonweight-based) dosing for the SC regimen administrated via handheld syringe. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quartino, Angelica L., Hillenbach, Carina, Li, Jing, Li, Hanbin, Wada, Russell D., Visich, Jennifer, Li, Chunze, Heinzmann, Dominik, Jin, Jin Y., Lum, Bert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706584/ https://www.ncbi.nlm.nih.gov/pubmed/26645407 http://dx.doi.org/10.1007/s00280-015-2922-5

Ejemplares similares

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2017)

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
por: Wang, Bei, et al.
Publicado: (2021)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe
por: Cherniakov, Irina, et al.
Publicado: (2021)

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
por: Lopez-Vivanco, G., et al.
Publicado: (2017)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
por: De Cock, Erwin, et al.
Publicado: (2016)

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
por: Rojas, Luis, et al.
Publicado: (2020)

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects
por: Struemper, Herbert, et al.
Publicado: (2015)

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
por: Schindler, Emilie, et al.
Publicado: (2018)

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
por: Van den Nest, Miriam, et al.
Publicado: (2019)

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
por: Kirschbrown, Whitney P., et al.
Publicado: (2018)

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
por: Demary, Winfried, et al.
Publicado: (2014)

Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
por: Garg, Amit, et al.
Publicado: (2013)

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
por: Papadmitriou, K., et al.
Publicado: (2015)

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
por: Hamizi, Salima, et al.
Publicado: (2013)

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2017)

The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home
por: Tjalma, WAA, et al.
Publicado: (2017)

Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe
por: Cohen, Yehuda Z., et al.
Publicado: (2022)

Exploration of an Alarm Sensor to Detect Infusion Failure Administered by Syringe Pumps
por: Wieduwilt, Florian, et al.
Publicado: (2022)

Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed-Dose Subcutaneous Formulation of Trastuzumab
por: Hourcade-Potelleret, F, et al.
Publicado: (2014)

Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma
por: Ferguson, Gary T, et al.
Publicado: (2018)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Particulate Contamination in Intravenous Drugs: Coring from Syringe Plunger
por: Singhal, S K
Publicado: (2010)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study
por: Ritchie, Bruce, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
por: Xu, Na, et al.
Publicado: (2014)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study
por: Jacquin, Jean-Philippe, et al.
Publicado: (2019)

ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol
por: Ntekim, Atara I., et al.
Publicado: (2020)

Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research
por: Lin, Hsiang-Wen, et al.
Publicado: (2023)

Smart syringe pumps for drug infusion during dental intravenous sedation
por: Seo, Kwang-Suk, et al.
Publicado: (2016)

Pharmacokinetics of recombinant human growth hormone administered by cool.click™ 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle
por: Brearley, Chris, et al.
Publicado: (2007)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j9soikaoaom7et81ni5j2qaqfg